A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 28; no. 15_suppl; p. 3014
Main Authors Weekes, C. D., Hegde, P., Xin, Y., Yu, R., Xiang, H., Beeram, M., Gore, L., Brachmann, R. K., Patnaik, A.
Format Journal Article
LanguageEnglish
Published 20.05.2010
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2010.28.15_suppl.3014